Payment overview · 2025
General Payments
$1,632.87
82 reported records · 29 companies
Healthcare provider profile · identity verified
Brian Campbell Jimenez, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PINE BLUFF, AR · NPI 1548668916
Verified facts
What the public records show
CMS Open Payments records show Brian Campbell Jimenez, M.D. received $1,632.87 in general payments during 2025 across 82 reported records.
Novartis Pharmaceuticals Corporation accounted for 17.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 48 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Erleada, Jakafi, Verzenio.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CALQUENCE as an associated drug or biological on 8404 records involving 3935 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Calquence by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Eliquis by this doctor in 2024.
Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JAKAFI as an associated drug or biological on 14854 records involving 6477 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Jakafi by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ERLEADA as an associated drug or biological on 32382 records involving 10919 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Erleada by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERZENIO as an associated drug or biological on 9278 records involving 4763 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Verzenio by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $282.01 | 17.3% | 18 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $185.13 | 11.3% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $152.25 | 9.3% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $80.53 | 4.9% | 4 | 2025 |
| PUMA BIOTECHNOLOGY, INC. | Unresolved — no canonical attribution shown | $65.85 | 4.0% | 4 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $64.74 | 4.0% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $56.03 | 3.4% | 3 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $53.44 | 3.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $51.89 | 3.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $51.71 | 3.2% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $45.65 | 2.8% | 3 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $42.54 | 2.6% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $40.84 | 2.5% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $37.62 | 2.3% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.71 | 2.2% | 2 | 2025 |
| Aveo Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.57 | 2.2% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $36.05 | 2.2% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $35.42 | 2.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.12 | 2.0% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $32.01 | 2.0% | 2 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $31.95 | 2.0% | 1 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $29.74 | 1.8% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $29.55 | 1.8% | 2 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $27.71 | 1.7% | 2 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $20.52 | 1.3% | 1 | 2025 |
| Geron Corporation | Unresolved — no canonical attribution shown | $20.43 | 1.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.61 | 1.1% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $17.56 | 1.1% | 1 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $16.69 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,606.92 | 81 |
| Education | $25.95 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ENHERTU Normalized: enhertu |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc. | $148.93 | 7 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Drug | Janssen Biotech, Inc. | $128.72 | 1 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $128.72 | 1 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $121.84 | 7 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $83.13 | 7 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $77.04 | 4 | 2025 |
Source payment records
|
|||||
| NERLYNX Normalized: nerlynx |
Drug | PUMA BIOTECHNOLOGY, INC. | $65.85 | 4 | 2025 |
Source payment records
|
|||||
| Onivyde Normalized: onivyde |
Drug | Ipsen Biopharmaceuticals, Inc | $64.74 | 4 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $60.03 | 2 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $53.44 | 2 | 2025 |
Source payment records
|
|||||
| Vyloy Normalized: vyloy |
Drug | Astellas Pharma US Inc | $45.65 | 3 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $42.54 | 2 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | ARRAY BIOPHARMA INC, PFIZER INC. | $41.51 | 2 | 2025 |
Source payment records
|
|||||
| WAYRILZ Normalized: wayrilz |
Drug | GENZYME CORPORATION | $40.84 | 1 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PFIZER INC. | $39.46 | 2 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $39.46 | 2 | 2025 |
Source payment records
|
|||||
| NINLARO Normalized: ninlaro |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $38.71 | 2 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Drug | ABBVIE INC. | $37.63 | 2 | 2025 |
Source payment records
|
|||||
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $37.29 | 2 | 2025 |
Source payment records
|
|||||
| ZEJULA Normalized: zejula |
Drug | GlaxoSmithKline, LLC. | $37.29 | 2 | 2025 |
Source payment records
|
|||||
| DANZITEN Normalized: danziten |
Drug | Azurity Pharmaceuticals, Inc. | $36.71 | 2 | 2025 |
Source payment records
|
|||||
| FOTIVDA Normalized: fotivda |
Drug | Aveo Pharmaceuticals, Inc. | $36.57 | 2 | 2025 |
Source payment records
|
|||||
| Tecentriq Normalized: tecentriq |
Biological | Genentech USA, Inc. | $36.05 | 1 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Biotech, Inc. | $34.08 | 1 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Lilly USA, LLC | $33.12 | 2 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Lilly USA, LLC | $33.12 | 2 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $32.01 | 2 | 2025 |
Source payment records
|
|||||
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $31.95 | 1 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc. | $29.74 | 2 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $29.55 | 2 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $27.71 | 2 | 2025 |
Source payment records
|
|||||
| AKEEGA Normalized: akeega |
Drug | Janssen Biotech, Inc. | $22.33 | 1 | 2025 |
Source payment records
|
|||||
| BALVERSA Normalized: balversa |
Drug | Janssen Biotech, Inc. | $22.33 | 1 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $22.33 | 1 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| RYTELO Normalized: rytelo |
Drug | Geron Corporation | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological | PFIZER INC. | $20.08 | 1 | 2025 |
Source payment records
|
|||||
| VIVIMUSTA Normalized: vivimusta |
Drug | Azurity Pharmaceuticals, Inc. | $19.54 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| SYLVANT Normalized: sylvant |
Drug | RECORDATI_RARE_DISEASES_INC. | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| FRUZAQLA Normalized: fruzaqla |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $17.32 | 1 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Drug | AstraZeneca Pharmaceuticals LP | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $14.60 | 1 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC. | $14.08 | 1 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $14.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ERLEADA erleada |
2025 | Erleada | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JAKAFI jakafi |
2025 | Jakafi | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VERZENIO verzenio |
2025 | Verzenio | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | CALQUENCE open payments reported associated product |
CMS Open Payments — General Payments 8404 supporting records · 3935 recipient NPIs · example record 1206131382 |
Calquence · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Incyte Corporation Exact reporting entity; no affiliate inference |
2025 | JAKAFI open payments reported associated product |
CMS Open Payments — General Payments 14854 supporting records · 6477 recipient NPIs · example record 1225959940 |
Jakafi · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | ERLEADA open payments reported associated product |
CMS Open Payments — General Payments 32382 supporting records · 10919 recipient NPIs · example record 1174257499 |
Erleada · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | VERZENIO open payments reported associated product |
CMS Open Payments — General Payments 9278 supporting records · 4763 recipient NPIs · example record 1186464449 |
Verzenio · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Anastrozole | Anastrozole | 106 | 30 |
| Ondansetron Odt | Ondansetron | 48 | 16 |
| Exemestane | Exemestane | 30 | suppressed |
| Gabapentin | Gabapentin | 24 | suppressed |
| Prednisone | Prednisone | 24 | 11 |
| Eliquis | Apixaban | 23 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 23 | suppressed |
| Erleada | Apalutamide | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Verzenio | Abemaciclib | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Jakafi | Ruxolitinib Phosphate | 12 | suppressed |
| Calquence | Acalabrutinib Maleate | 11 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,632.87 · 82 records | Novartis Pharmaceuticals Corporation | ADCETRIS, AKEEGA, BALVERSA, BESREMI, BRAFTOVI, BRUKINSA, CABOMETYX, CARVYKTI, DANZITEN, ELREXFIO, ENHERTU, EPKINLY, ERLEADA, FOTIVDA, FRUZAQLA, Fabhalta, IBRANCE, IMBRUVICA, IMFINZI, JAKAFI, JAYPIRCA, JEMPERLI, KEYTRUDA, KISQALI, LIBTAYO, LYNPARZA, Lenvima, MEKTOVI, NERLYNX, NINLARO, OJJAARA, Onivyde, PADCEV, REBLOZYL, RYBREVANT, RYTELO, SCEMBLIX, SYLVANT, TECVAYLI, TUKYSA, Tecentriq, Trodelvy, VENCLEXTA, VERZENIO, VIVIMUSTA, Vyloy, WAYRILZ, ZEJULA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Erleada play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error